Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 4
2006 3
2007 2
2008 1
2010 3
2011 2
2012 5
2013 5
2014 4
2015 1
2016 5
2017 8
2018 12
2019 10
2020 13
2021 9
2022 11
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials.
Kim Y, Keam B, Kang EJ, Kim JS, Kim HR, Lee KW, Kwon JH, Lee KE, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Choi MY, Lee KH, Kim SB, Ahn MJ. Kim Y, et al. Among authors: kang ej. Cancer Res Treat. 2024 Apr 15. doi: 10.4143/crt.2024.008. Online ahead of print. Cancer Res Treat. 2024. PMID: 38637966 Free article.
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
Kim JW, Lee HJ, Lee JY, Park SR, Kim YJ, Hwang IG, Kyun Bae W, Byun JH, Kim JS, Kang EJ, Lee J, Shin SJ, Chang WJ, Kim EO, Sa JK, Park KH. Kim JW, et al. Among authors: kang ej. J Immunother Cancer. 2024 Mar 13;12(3):e008638. doi: 10.1136/jitc-2023-008638. J Immunother Cancer. 2024. PMID: 38485184 Free PMC article. Clinical Trial.
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
Kim DH, Lim ST, Kim HR, Kang EJ, Ahn HK, Lee YG, Sun S, Kwon JH, Lee SC, Lee HW, Kim MK, Keam B, Park KU, Shin SH, Yun HJ. Kim DH, et al. Among authors: kang ej. Oral Oncol. 2024 Apr;151:106739. doi: 10.1016/j.oraloncology.2024.106739. Epub 2024 Mar 7. Oral Oncol. 2024. PMID: 38458039 Clinical Trial.
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Park S, et al. Among authors: kang ej. J Clin Oncol. 2024 Apr 10;42(11):1241-1251. doi: 10.1200/JCO.23.01891. Epub 2023 Oct 20. J Clin Oncol. 2024. PMID: 37861993 Clinical Trial.
Catechol-Amyloid Interactions.
Le NTK, Kang EJ, Park JH, Kang K. Le NTK, et al. Among authors: kang ej. Chembiochem. 2023 Dec 14;24(24):e202300628. doi: 10.1002/cbic.202300628. Epub 2023 Oct 31. Chembiochem. 2023. PMID: 37850717 Review.
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma.
Kim DH, Lim Y, Ock CY, Park G, Park S, Song H, Ma M, Mostafavi M, Kang EJ, Ahn MJ, Lee KW, Kwon JH, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Kim SB, Keam B. Kim DH, et al. Among authors: kang ej. Head Neck. 2023 Dec;45(12):3086-3095. doi: 10.1002/hed.27537. Epub 2023 Oct 13. Head Neck. 2023. PMID: 37828867 Clinical Trial.
95 results